By 2022, it is anticipated that the Herpes Simplex Keratitis Treatment Market would reach US$ 4.2 billion. Market size is estimated to reach US$ 7.9 billion in 2032 and grow at a robust CAGR of 6.1% between 2022 and 2032.One of the main causes of ocular morbidity worldwide, along with CMV retinitis in AIDS, is human.
Oslo, 16 February 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the fourth quarter of 2022. In the period, Navamedic delivered another quarter with solid growth across its portfolio, resulting in a 29 per cent increase in revenues to NOK 116.0 million compared to the same quarter in 2021. For the full year of 2022, revenues amounted to NOK 382.1 million, up 37 per cent compared to 2021.
/PRNewswire/ Oslo, 1 November 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and.
/PRNewswire/ Navamedic has signed an agreement with the French pharmaceutical company Vectans Pharma, which gives Navamedic the exclusive right to market.